University of Miami's 2nd Biennial Miami Leukemia Symposium
Relapsed/Refractory ALL: Both Inotuzumab and Blinatumomab Are Superior to Standard Chemotherapy With Regards to Remission Rates and Survival
Login to view comments.
Click here to Login
